AGU

AMINOGUANIDINE

Created:1999-07-08
Last modified:  2011-06-04

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count11
Chiral Atom Count0
Bond Count10
Aromatic Bond Count0
2D diagram of AGU

WebGL does not seem to be available.

This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.

For a list of supported browsers, refer to http://caniuse.com/#feat=webgl.

Toggle HydrogenToggle Labels

Chemical Component Summary

NameAMINOGUANIDINE
Systematic Name (OpenEye OEToolkits)1-aminoguanidine
FormulaC H6 N4
Molecular Weight74.085
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs10.04[N@H]=C(N)NN
SMILESCACTVS3.341NNC(N)=N
SMILESOpenEye OEToolkits1.5.0C(=N)(N)NN
Canonical SMILESCACTVS3.341 NNC(N)=N
Canonical SMILESOpenEye OEToolkits1.5.0 C(=N)(N)NN
InChIInChI1.03 InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
InChIKeyInChI1.03 HAMNKKUPIHEESI-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB05383 
NamePimagedine
Groups investigational
DescriptionPimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Synonyms
  • Aminoguanidine
  • Pimagedine
  • Pimagedine hydrochloride
  • Hydrazinecarboximidamide
  • Monoaminoguanidine
IndicationInvestigated for use/treatment in diabetic kidney disease.
Categories
  • Amidines
  • Enzyme Inhibitors
  • Nitric Oxide Synthase, antagonists & inhibitors
  • OCT2 Inhibitors
CAS number79-17-4

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Nitric oxide synthase, inducibleMACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLS...unknowninhibitor,downregulator
C-C chemokine receptor type 2MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYS...unknownantagonist
Diamine oxidase [copper-containing]MPALGWAVAAILMLQTAMAEPSPGTLPRKAGVFSDLSNQELKAVHSFLWS...unknowninhibitor
Aldo-keto reductase family 1 member B1MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQ...unknown
Metalloproteinase inhibitor 3MTPWLGLIVLLGSWSLGDWGAEACTCSPSHPQDAFCNSDIVIRAKVVGKK...unknown
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL225304
PubChem 2146
ChEMBL CHEMBL225304
ChEBI CHEBI:40618
CCDC/CSD RAGNEU, HAFSOW03, VAGSIG, HAFSOW02, FIWQEH, AMGUAC03, HIRPUT, CEXZAH, GILZUZ, POCJAS, HAFSOW01, HELHUD, FUFDES, TIVJEN, AGUAHP01, HEQBUA, GOQZUK, QUJDAB, SIGGOF, HIPTIM, EXIGIC, YANRIQ, FUDWUY, GEMHAK, CIWVOV, HELJIT, GUFFAP, BAHPEG, GILZUZ01, HAFSOW, KOJVEK, CIWNUT, APITAW, EFOCAE, DUBSEY, CAZCUD, ICASUC, BEMCIH01, MIPZOD, BEMCIH, FAJFOO, VECGER, EWADOX, GIMBAI, KOJVAG, CEKBIF, COXYAQ, GOLXUB, AMGUAC02, DIDSIT, DOXJUW, GOCXUU, HELKAM, FIFYIE, HEQBUA01, ZOSHIY, ARAQIV, GEMNUK, FERFEP, HELHUD01, EDEHON, CANJIN, AVOBOF, AWEBOW, HAGKUZ, ESOXOC, ANITOJ